Maykelyn Felipe
Psychiatric/Mental Health · Delray Beach, FLNPI 1528575925
Payments from drug & device makers
Across 335 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$602
- Vanda Pharmaceuticals Inc.$501
- Corium, LLC$388
- Almatica Pharma LLC$329
- Takeda Pharmaceuticals U.S.A., Inc.$301
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,971100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $1,673 |
| Otsuka America Pharmaceutical, Inc. | 31 | $602 |
| Vanda Pharmaceuticals Inc. | 24 | $501 |
| Corium, LLC | 34 | $388 |
| Almatica Pharma LLC | 18 | $329 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $301 |
| Lundbeck LLC | 10 | $253 |
| Supernus Pharmaceuticals, Inc. | 7 | $224 |
| Teva Pharmaceuticals USA, Inc. | 11 | $222 |
| Alkermes, Inc. | 11 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $207 |
| Orexo US, Inc. | 11 | $204 |
| Johnson & Johnson | 8 | $201 |
| Braeburn Inc. | 8 | $171 |
| Indivior Inc. | 7 | $142 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Eisai Inc. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Bausch Health US, LLC | 2 | $36 |
| Tempus AI, Inc | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,983 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 37 | $59,232 |
| RexultiBrexpiprazole | 20 | $28,459 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 113 | $20,306 |
| LatudaLurasidone Hcl | 14 | $18,717 |
| TrintellixVortioxetine Hydrobromide | 22 | $13,486 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $10,379 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $9,040 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $7,071 |
| Buprenorphine Hcl | 92 | $5,358 |
| Chlorpromazine Hcl | 19 | $4,391 |
| Lurasidone Hcl | 18 | $3,660 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 122 | $3,567 |
| Aripiprazole | 147 | $3,301 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 13 | $2,767 |
| Lamotrigine ErLamotrigine | 11 | $2,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,673 | $59,23237 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $602 | $28,45920 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $15 | $25,663205 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $301 | $20,55740 claims |
| Orexo US, Inc.Zubsolv | $204 | $10,37912 claims |
| Indivior Inc.Suboxone | $142 | $9,04014 claims |
| Almatica Pharma LLCSertraline Hcl | $329 | $863122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Delray Beach
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.